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REIMBURSEMENT RECOMMENDATION PROCESS IN BRAZIL: CITEC 
SUBMISSIONS PROFILE
Araújo GTBD, Fonseca M
AxiaBio, São Paulo, Brazil
OBJECTIVES: To access and understand the main characteristics of the Reimburse-
ment submission process and HTA recommendations in Brazil. METHODS: This is 
a crossed analysis of secondary data displayed by the Brazilian new technology incor-
poration committee (CITEC) regarding the quantity and characteristics (disease, sub-
mitter, type of health technology, and year of submission) of the submitted protocols 
versus quantity and characteristics of the recommended health technologies. RESULTS: 
In 3 years of existence, 216 Health technologies (mean of 48 submissions per year) were 
appraised by the commission resulting in 22 positive recommendations and XX Negative 
recommendations. For the reconvened Health technologies, the median time from sub-
mission and recommendation was 1 year. Oncology and Rheumatology are the main 
submissions groups by disease (12% and 11%, respectively) and Hepatology and 
Rheumatology are the most recommended groups by disease (18% and 14% respec-
tively). Manufacturers are the main submitters (74%), followed by the own federal 
government. 5% of the submissions was made by mixed submitters that can be chac-
terized by research partnerships between manufacturers, academia and government. 
CONCLUSIONS: This ﬁ nds suggests that the conduction of HTA recommendation 
and adoption process is already a reality in Brazil and the decisions are based not 
anymore only in political issues but are strongly based on clinical and economical 
issues too. As a new process in the country, modiﬁ cations as time to response and 
establishment of a Brazilian ICER during the next years can improve the results for 
CITEC and submitters.
HEALTH CARE USE & POLICY STUDIES – Formulary Development
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CURRENT AND FUTURE USE OF PHARMACOECONOMIC AND 
OUTCOMES RESEARCH DATA IN DECISION-MAKING IN THE USA
Holtorf AP1, Keskinaslan A2, Biskupiak J3, Brixner D4
1Health Outcomes Strategies GmbH, Basel, Switzerland; 2Novartis Pharma AG, Basel, 
Switzerland; 3University of Utah College of Pharmacy, Salt Lake City, UT, USA; 4University of 
Utah, Salt Lake City, UT, USA
OBJECTIVES: To understand how PEOR data are used in decision making today and 
how this may change in future. The methodology and quantity of Pharmacoeconomics 
and Outcomes Research (PEOR) has advanced considerably over the last decade. With 
increasing utilization of health care, prioritization becomes unavoidable and PEOR 
evidence should be increasingly valuable to supplement efﬁ cacy and safety data for 
reimbursement and access decisions. METHODS: An internet based survey with 30 
items was conducted among decision makers from the USA in April 2010. RESULTS: 
The 76 respondents represented organizations with national (54%), regional (32%) or 
local coverage (14%). Membership varied from 50,000 to 100million with a median of 
500,000. While 70% of the respondents claimed that PEOR data are used regularly, 
only 5% indicated coverage by the bylaws of their organizations, and 66% of the users 
indicated that there is no quality standard for PEOR being used by the organization. 
The majority of the respondents expected increasing use of PEOR in the future (77%). 
Organizational requirements to such adoption included ‘more HEOR expertise’, better 
deﬁ nitions and standards of methods, in-house data analysis expertise, and regular re-
evaluation. Outcomes based evidence is increasingly used in contracting (37%) and 73% 
expected an increased use in future with the perceived value of reduced ﬁ nancial and 
clinical risk. CONCLUSIONS: PEOR is used often in decision making in the USA. 
However, few organizations deﬁ ned quality criteria for PEOR. There is a consistent 
expectation that there will be an increasing use of this data, along with a concern 
regarding a lack of expertise to evaluate this information in their organizations. 
Improved standards for quality control of such evidence are needed. Another survey will 
be targeted to the systems and decision makers in selected European countries to 
compare the utilization of PEOR in the different decision making environments.
PHP43
ASSESSING THE ADDED VALUE OF NEW DRUGS: A 
MULTIDIMENSIONAL APPROACH
Paladio N, Sunyer B, Almazan C, Solà-Morales O
Catalan Agency for Health Technology and Research, Barcelona, Spain
OBJECTIVES: In November 2008, the Program for the Assessment, Monitoring and 
Reimbursement of High Complexity Drugs (PASFTAC) took effect in Catalonia and 
the Committee for the Assessment of Hospital Use Drugs (CAMUH) was consequently 
appointed to give recommendations on medicines use. Our aim is to develop a tool 
that embraces the multidimensional aspects of added value in drug assessment. 
METHODS: A qualitative approach (adapted expert panel) has been used. Partici-
pants included decision makers, health economists, experts on bioethics, clinicians and 
pharmacists. A previous detailed review of literature was conducted for the topic under 
discussion. RESULTS: Several dimensions and items were identiﬁ ed and discussed in 
a single meeting. Main identiﬁ ed dimensions included efﬁ cacy, safety and cost-effec-
tiveness as well as clinical relevance of outcomes, unmet therapeutic needs, ethics, and 
cost-oportunity. Individual interviews were further conducted. Discussion and rating 
of dimensions and items within these will be performed in a second meeting. A pilot 
test will be conducted after a minimum of 10 drugs are assessed by the CAMUH 
(expected by September 2010). CONCLUSIONS: In a context of limited evidence 
dimensions other than classical efﬁ cacy, safety and cost-effectiveness need to be con-
sidered at the time of assessing added value. This new tool will contribute to that task 
and standardize the process at a local level. 
HEALTH CARE USE & POLICY STUDIES – Health Care Costs & 
Management
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APPLICATION OF PERATO’S PRINCIPLE TO UNDERSTAND COST 
DRIVERS IN HEALTH CARE
Long S1, Misra A2
1Thomson Reuters, Cambridge, MA, USA; 2Thomson Reuters, Washington, DC, USA
OBJECTIVES: To determine if Pareto’s principle (also known as the 80–20 rule) applies 
to health care expenditures in the US, and to describe the patients and treatments 
considered to be “cost drivers.” METHODS: The study population consisted of persons 
<65 years that were continuously enrolled in the Thomson Reuters MarketScan Com-
mercial Database during the years 2004–2008. Individuals were rank ordered highest 
to lowest according to their 2008 health care expenditures and assigned to the Cost 
Driver (CD) Cohort if their costs were within the 80% cumulative sum of the overall 
total expenditures. Clinical and cost characteristics were compared between 2004 and 
2008 using Compound Annual Growth Rates (CAGR). RESULTS: 2008 total expen-
ditures were $27.5M among 4.2M covered lives; the CD cohort represented 27% of the 
overall study population. Mean annual expenditures in the CD Cohort were $15,581 
(16.1% CAGR). Outpatient services, inpatient services, and outpatient pharmaceutical 
prescriptions represented 42%, 29% and 28% of total expenditures in 2008. From 2004 
to 2008, pharmaceutical expenditures grew 23% CAGR, while outpatient and inpatient 
expenditure growth was 15% and 13% respectively. Drivers of medical service expen-
ditures in the CD group were visits related to osteoarthritis, renal failure, vaginal deliver-
ies, bone and joint disorders, and low back pain. Drivers of outpatient pharmaceutical 
expenditures in the CD group were antihyperlipidemics, gastrointestinal drugs, antide-
pressants, antidiabetic agents, and anticonvulsants. CONCLUSIONS: In a large US 
database of commercially insured persons, 27% of individuals were accountable for 
80% of health care costs incurred during the year 2008. Payers should consider targeted 
interventions for their cost driver populations; for example, intense targeted programs 
aimed at reducing obesity could yield large cost offsets since much of the incurred costs 
were for treatment of conditions that are sequelae of obesity.
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COSTS OF CARE UNDER A HEALTH CARE PLAN IN THE LAST 5 YEARS 
OF LIFE OF BENEFICIARIES—DATA FROM THE REAL WORLD
Reis Neto J, Stefani S
CAPESESP/CAPESAUDE, Rio de Janeiro, RJ, Brazil
OBJECTIVES: To examine, in the ‘real-world’ scenario of a Brazilian health care plan, 
the effect of proximity to death in beneﬁ ciaries on health expenditure during the last 
5 years of life. METHODS: Retrospective analysis from data stored on the comput-
erised system of the health care plan of 1897 beneﬁ ciaries who died between January 
2007 and June 2009. The outpatient and hospital health services in the year of death 
and in the 4 preceding years were examined. The analysis was restricted to total direct 
costs with medical-hospital care. The variables (demographic, clinical and costs) were 
subjected to statistical treatment considering a conﬁ dence interval of 95%. RESULTS: 
Out of a total of 1897 deaths analyzed, the majority were male (60.4%) and were 
aged 60 or over (77.0%). The overall mean age of the deceased was 70.6 years (CI95% 
69.9–71.4). The cost over the 60 months of the study was US$64,427,852. This total, 
66.8% was reimbursed in the year of death and the clinical admissions corresponded 
to 89.2% of the total. Among the main causes of death, neoplasia and chronic diseases 
had a heavier inﬂ uence on expenditure. CONCLUSIONS: The rise in spending on 
health appears to be directly associated with the effect of increased age together with 
a second factor considered to be important, the proximity to death. It is estimated 
that in 2050 Brazil will have a population of 64 million individuals aged 60 or over, 
representing one of the main challenges to the adequate allocation of resources. This 
study suggests that the costs in the last year of life should be considered in the projec-
tions for spending on health care, in the same way as the ageing factor. One of the 
alternatives that appears to be important at the end of life is palliative care.
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COSTS OF TREATING TERMINAL PATIENTS IN DIFFERENT BELGIAN 
HEALTH CARE SETTINGS
Simoens S1, Kutten B2, Menten J2
1K.U. Leuven, Leuven, Belgium; 2University Hospitals Leuven, Leuven, Belgium
OBJECTIVES: This study aims to measure the costs of treating terminal patients in 
Belgian hospitals and in nursing homes from the health care payer perspective. Also, 
this study compares the costs of palliative care with those of usual care. METHODS: 
A multi-centre, retrospective cohort study enrolled patients in acute wards and in 
palliative care units from a representative sample of hospitals and from a representa-
tive sample of nursing homes. Health care costs included ﬁ xed costs and charges 
relating to medical fees, pharmacy and other charges. Data sources consisted of 
hospital and nursing home accountancy data and patient invoice data. The price year 
was 2007/2008. RESULTS: Six hospitals and nineteen nursing homes participated in 
the study, generating a total of 327 patients. Mean hospital costs per patient per day 
amounted to c391 (± c156). Mean hospital costs of patients receiving usual care in 
an acute ward (c340 ± 143) exceeded costs of palliative care in an acute ward (c283 
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± 109) (P = 0.025). Mean nursing home costs amounted to c3243 (±2700) per patient 
during the ﬁ nal month of life. Mean nursing home costs per patient of c3822 (±3232) 
for patients receiving usual care were higher than costs of c2456 (±2117) for patients 
receiving palliative care (P = 0.068). CONCLUSIONS: This study suggests that pallia-
tive care models in acute hospital wards and in nursing homes need to be supported 
because such care models appear to be less expensive than usual care and because 
such care models are likely to better reﬂ ect the needs of terminal patients.
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EFFICIENCY IN DRUG PRESCRIPTION MEASURED BY THE 
APPLICATION OF ADJUSTED CLINICAL GROUPS IN THIRTEEN 
SPANISH PRIMARY CARE CENTRES
Sicras-Mainar A1, Velasco-Velasco S2, Llopart-López JR2, Navarro-Artieda R3, 
Blanca-Tamayo M2
1Directorate of Planning, Badalona Serveis Assistencials, Badalona, Barcelona, Spain; 
2Badalona Serveis Assistencials SA, Barcelona, Spain; 3Hospital Universitari Germans Trias i 
Pujol, Barcelona, Spain
OBJECTIVES: To measure the efﬁ ciency of pharmacy resources utilization in 13 
Primary Care centres by the retrospective application of Adjusted Clinical Groups (ACG) 
in a usual clinical practice setting. METHODS: Retrospective study carried out on the 
basis of the clinical records from all the attended patients along the year 2008. Main 
variables: age, sex, case-mix/episodes, visits, pharmacy costs, 13 centres, physician and 
service (Family Medicine or Paediatrics). ACG grouper (Starﬁ eld and Weiner, Johns 
Hopkins University, n = 106) classiﬁ es each patient in a unique category of similar 
resource consumption. A Receiver Operating Characteristics (ROC-area under the 
curve) analysis was done to assess the predictive value of the model. The Efﬁ ciency Index 
(EI) was obtained as the quotient between the observed and the expected pharmacy 
costs according to ACG distribution (indirect standardization). The statistical package 
SPSS was used (P < 0.05). RESULTS: A total of 227,235 patients were included. Average 
number of episodes 4.5 ± 3.2 and visits 8.1 ± 8.2; mean age: 44.1 ± 23.7 years; and 
55.6% of males. Intensity of utilization: 77.4%. Costs of drug prescription: c70.6 mil-
lions (47.6% of the total costs). Mean cost was c310.8 ± 681.2. ROC curve analysis 
for episodes: 0.588 (p = 0.001); sensibility: 37.3%, speciﬁ city: 73.1% and intra-class 
correlation coefﬁ cient C: 0.732 (P < 0.001). The EI for each centre was analyzed, P < 
0.0001. Furthermore, differences between family physicians and paediatricians were 
observed (range: 0.55–1.46), P < 0.001. CONCLUSIONS: Results show a wide vari-
ability in the costs of pharmacy within centres and physicians. ACG provide an adjusted 
approximation to efﬁ ciency in pharmacy costs. Efﬁ ciency must not be considered as an 
isolated dimension of quality. The determination of the El could lead to a better knowl-
edge of the prescription proﬁ le from individual physicians and/or primary care teams.
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ECONOMIC EVALUATION OF HEALTH CARE INTERVENTIONS DURING 
MORE THAN 25 YEARS IN SPAIN (1983–2008)
Catalá-López F1, Garcia-Altés A2
1Spanish Medicines and Healthcare Products Agency (AEMPS), Madrid, Spain; 2King’s College 
London, London, UK
OBJECTIVES: Economic evaluation has been promoted as a tool to guide decision-
making processes regarding health care resources’ allocation and in the adoption of 
health care technologies. We analyzed the evolution and the main characteristics of 
economic evaluations of health care interventions done during the period 1983–2008 
in Spain. METHODS: Observational descriptive study. We performed a systematic 
review in the main bibliographic databases (PubMed/MEDLINE, SCOPUS, ISI Web of 
Knowledge, CRD, IME, IBECS) and manually through Internet in journals and public 
reports. There were predeﬁ ned inclusion and exclusion criteria, and a set of variables 
to analyze the characteristics of the selected reports. RESULTS: In total, 477 studies 
fulﬁ lled inclusion criteria. Some of the studies characteristics were: cost-effectivenes 
analysis (62.5%), decision analysis techniques (34.0%), heath care system perspective 
(42.1%), therapeutic interventions (70.0%) and non explicit ﬁ nancing (44.0%). The 
geographical distribution for Spanish regions of the ﬁ rst authors was: Catalonia 
(29.3%), Community of Madrid (23.7%), Andalusia (6.7%) and Region of Valencia 
(6.3%). a total of 50.9% of the principal authors were employed at hospital centers. 
The most commontly disease conditions were: cardiovascular diseases (15.7%), infec-
tious and parasitic diseases (15.3%) and malignant neoplasms (13.2%). a total of 82.2% 
of the reports provided recommendations guide for decision making. CONCLUSIONS: 
An increasing number of studies was observed. Identiﬁ ed reports combined heterogene-
ity in the quality of the information brought with regard to analysis methods, data 
sources, type of interventions, or disease conditions. It is suggested to do more efforts 
for improving the quantity and quality of reports in public health interventions.
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INFLUENCE OF THE CHRONIC DISEASE IN HEALTH RESOURCES USE: 
ECONOMICS CONSECUENCES AND RISK STRATIFICATION
Sicras-Mainar A1, Navarro-Artieda R2, Baulenas-Parellada D3, Frías-Garrido X3, Perez S3
1Directorate of Planning, Badalona Serveis Assistencials, Badalona, Barcelona, Spain; 2Hospital 
Universitari Germans Trias i Pujol, Barcelona, Spain; 3Directorate of Primary Care. Badalona 
Serveis Assistencials SA, Barcelona, Spain
OBJECTIVES: The Chronic disease are ones of high prevalence, duration and slow 
progression, its cure could not be predicted clearly or will never be. In general, are 
related to lifestyles and population that is older. To determine the direct sanitary cost 
depending on chronic comorbidity grade (risk) in patients attended in a primary care 
setting (PC). METHODS: Retrospective multicentre design. Patients over 14 years 
were included, pertaining at 6 PC teams that demand assistance during year 2008. 
Main measures: sociodemographics, risk/casuistic/comorbidity, Charlson index (sever-
ity) and direct cost models. The chronic comorbidity was classiﬁ ed beginning from 
Adjusted Clinical Groups. It was obtained the Resources Utilization Bands (RUB) per 
patient (rank: 1- healthy user to 5- high morbidity). The complexity/comorbidity was 
grouped in 10 categories (6 expert forum). Fixed/semi ﬁ xed cost were considered 
(functioning: salary, services, purchases) and variable (tests, referrals, drugs). Explana-
tion power calculation: determination coefﬁ cient (R2). It was made an ANOVA analy-
sis for the correction (age, sex, comorbidity) of the models (procedure: Bonferroni). 
SPSSWIN program; P < 0.05. RESULTS: A total of 69,653 patients, age-average: 47.6 
± 18.8 years; women: 54.1%; high morbidity: 4.8%; chronic disease: 3.8 ± 2.3 and 
total cost: c51.3 million (ﬁ xed cost: 12.3%). The 35.4% (n = 24,670; CI: 34.5–36.3%) 
showed ≥5 chronic disease. Binary correlations: comorbidity-BUR: 0.716; cost-comor-
bidity: 0.596; age-comorbidity: 0.429; P < 0,001. Osseo-muscular illness (38.1%), 
mental (31.6%) and cardiovascular (30.4%) were the same frequencies, P < 0.001. 
The unitary average of the cost corrected was of c736.74 ± c921.97, with comorbidity 
ranks between: 1 = 309.62; 5 = 842.99; 10 = c2,354.05, respectively, P < 0.001. 
Predictive model (R2): age = 25.7%; age-sex = 26.5%; age-sex-comorbidity = 60.3%, 
of the cost. Women showed more comorbidity. CONCLUSIONS: Chronic comorbid-
ity is associated with a sanitary cost increase. The number of comorbidities explains 
the major part of the cost. Patient knowledge of risk/complexity enable us doing dif-
ferent strategies of preventive/cure intervention. KEY WORDS: comorbidity, cost, 
resource use, risk.
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FRAGMENTED HEALTH CARE SYSTEM—SOLVING THE JIGSAW PUZZLE
Miksch F1, Urach C1, Popper N2, Weisser A3, Endel G3
1Vienna University of Technology, Vienna, Austria; 2Dwh Simulation Services, Vienna, Austria; 
3Main Association of Austrian Social Security Institutions, Vienna, Austria
OBJECTIVES: Austria’s health insurance system is divided into 13 sickness funds. 
Each fund has its own fee structure with individual names and codes for every pro-
cedure performed in an outpatient setting. Outpatient setting includes general practi-
tioners, specialists, ambulatories and institutes. Each sickness fund has general 
contracts for GPs and specialists while each institute has its own contract. These 
contracts partly include procedures that are not comparable with any procedures of 
other sickness funds. Some sickness funds pay physicians and institutes different fees 
for same procedures. Moreover, the payment depends on the number of procedures 
performed by a physician or institute within a certain period of time. In order to 
evaluate procedure data, the so called meta-fee-structure, a set of pre-deﬁ ned, stan-
dardized procedures that are mapped by individual fee-structures, was developed. 
METHODS: Given data with frequencies and costs of procedures for every sickness 
fund we are going to propose methods for examining and compare these data: Com-
paring the cumulative costs, frequencies, the average rates for procedures and the rates 
for different institutes and physicians paid by different sickness funds. All methods 
are then applied on real data in the ﬁ eld of radiology. RESULTS: By using this process 
with real world data it is possible to show the potential of these methods, lacks in 
data quality and the limitations of the meta-fee structure. Furthermore it is possible 
to point out proposals where procedure costs should be examined more closely and 
maybe health care costs could be reduced. CONCLUSIONS: Due to the heterogeneous 
health care system of Austria there is a wide variety of issues to be addressed when 
analyzing data. Although the proposed methods are very general they have to be 
adapted to the actual problems. Knowledge about data origin is crucial when choosing 
methods to get high quality results.
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ROUTINE REPLACEMENT OF PERIPHERAL INTRAVENOUS CATHETER 
VERSUS CLINICALLY INDICATED REPLACEMENT: A COST 
COMPARISON STUDY FROM THE PUBLIC PAYER PERSPECTIVE
Tolentino ACM, Takemoto ML, Fernandes RA, Passos RB, Cukier FN
ANOVA—Knowledge Translation, Rio de Janeiro, RJ, Brazil
OBJECTIVES: IV catheterization is the most common invasive procedure among 
hospitalized patients and the widest practiced to prevent complications is routine 
replacement of the catheter (RCC) in ﬁ xed intervals. a meta-analysis (Webster 2008) 
showed no signiﬁ cant differences in terms of efﬁ cacy from RCC and replacement only 
when clinically indicated (RCI). This study aims to compare costs and consequences 
of RCC versus RCI from the public payer perspective. METHODS: Efﬁ cacy data was 
obtained from Webster 2008 which showed no clinical beneﬁ ts of RCC over RCI. 
Data from the Brazilian Hospital Information System (SIH/DATASUS) from January 
1–December 31, 2009 was used to deﬁ ne the annual number of admissions of adult 
patients in public hospitals wards, assuming RCC as the current practice (no ICU 
patients included). The mean length of stay (LOS) and the mean time to replacement 
(TTR) were used to calculate the number of replacements in each scenario. Resource 
utilization was estimated through published data and unit costs were obtained from 
Brazilian ofﬁ cial price lists. RESULTS: A total of 8,985,758 hospitalizations were 
identiﬁ ed in the database in 2009 with mean LOS of 5.53 days (132.66 hours). 
According to a published randomized clinical trial included in Webster 2008, mean 
TTR for RCC and RCI was 66.5 and 90.6 hours, respectively, resulting in average 
1.99 and 1.46 replacements per hospitalization in each setting. The estimated cost of 
replacement was 2.54BRL (nursing time and medical supplies). For all admissions, the 
total cost for RCC and RCI was 45,556,510BRL and 33,438,277BRL. The estimated 
